Novo Nordisk A/S (NYSE:NVO) Stock Position Decreased by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 29.5% during the fourth quarter, Holdings Channel reports. The fund owned 14,329 shares of the company’s stock after selling 5,984 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Novo Nordisk A/S were worth $1,184,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Daiwa Securities Group Inc. acquired a new stake in Novo Nordisk A/S in the 3rd quarter valued at approximately $28,000. Center for Financial Planning Inc. grew its holdings in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $42,000. Dunhill Financial LLC grew its holdings in shares of Novo Nordisk A/S by 196.8% during the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock worth $56,000 after purchasing an additional 311 shares in the last quarter. Finally, Albion Financial Group UT grew its holdings in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 1.4 %

Shares of NVO opened at $89.42 on Tuesday. The stock has a fifty day moving average price of $84.84 and a two-hundred day moving average price of $106.18. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. Novo Nordisk A/S has a 52-week low of $77.82 and a 52-week high of $148.15. The company has a market cap of $401.28 billion, a price-to-earnings ratio of 27.18, a PEG ratio of 0.90 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio is 47.72%.

Wall Street Analyst Weigh In

NVO has been the topic of several recent analyst reports. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.